Vyne Therapeutics INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
OrbiMed Advisors LLC and affiliated entities have filed a Schedule 13D, disclosing beneficial ownership of approximately 9.97% of Yarrow Bioscience, Inc. common stock following a merger.
NASDAQ
SCHEDULE: Yarrow Bioscience Stakeholder Update
AI Biotechnology LLC and affiliated entities report a 6.02% stake in Yarrow Bioscience, Inc. following a merger and stock split.